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BACKGROUND: Increased secretion  of mucus  is  a  hall-
mark  of many  respiratory  diseases  and contributes
significantly to the airflow limitation experienced by
many  patients.  While  the  current  pharmacological
approach to reducing mucus and sputum production
in patients is limited, clinical studies have suggested
that drugs which inhibit the cyclooxygenase and/or
5-lipoxygenase  enzymatic  pathways  may  reduce
secretory activity in patients with airway disease.
Aim:  This  study  was  performed  to  investigate  the
effects  of  indomethacin  (cyclooxygenase  inhibitor)
and Bay x1005 (5-lipoxygenase inhibitor) on MUC5AC
release from human airways in vitro.
Methods: An immunoradiometric  assay was used to
determine the quantities of MUC5AC present in the
biological fluids derived from human airways in vitro.
The measurements were made with a mixture of eight
monoclonal antibodies (MAbs; PM8) of which the 21
M1  MAb  recognized  a  recombinant  M1  mucin  par-
tially encoded by the MUC5AC gene.
Results:  The  quantities  of  MUC5AC  detected  in  the
biological fluids derived from human bronchial pre-
parations  were  not  modified  after  treatment  with
indomethacin (cyclooxygenase inhibitor) and/or an
inhibitor  of  the  5-lipoxygenase  metabolic  pathway
(BAY x1005).
Conclusion:  These  results  suggest  that  the  cycloox-
ygenase and 5-lipoxygenase metabolic pathways play
little or no role in the release of MUC5AC from human
airways.
Key words: MUC5AC  mucin, Human airways,  Secretion,
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Introduction
An increase in the quantities of the metabolites of the
cyclooxygenase and 5-lipoxygenase enzymatic path-
ways has been demonstrated in sputum derived from
asthmatic patients1,2 and patients with chronic bron-
chitis.3,4 In clinical studies,5 involving patients treated
with  inhibitors  of  these  enzymatic  pathways,  a
significant  reduction  in  sputum  volume  has  been
reported. These observations suggest that eicosanoids
may be involved in airway inflammation and modify
the secretory activity in the human respiratory tract.
While inhibition of eicosanoids has been reported
to alter a number of physiological responses in the
lung,6 there is limited information available concern-
ing  such  inhibition  on  secretory activity  in  human
airways.7,8 Initial reports have indicated that exposure
of  human  airway  cultured  cell  explants  to  indom-
ethacin caused an increase in mucus secretion, when
the incorporation of 3H-glucosamine was used as the
index  of  glycoprotein  secretory  activity.8 However,
these  data  were  obtained  in  tissues  constantly
exposed to hydrocortisone and therefore the direct
effects of indomethacin may be compromised by the
continuous steroid exposure. In fact, steroid inhala-
tion or  injection has been reported to significantly
reduce sputum production in asthmatic patients2 and
in isolated human airways, steroids also significantly
reduced glycoprotein secretion.9 These data suggest
that further studies concerning the effects of inhibi-
tion  of  the  cyclooxygenase  and/or  lipoxygenase
pathways  on  secretory  activity  may  be  warranted
since  there  remains  considerable  controversy  con-
cerning  such  inhibition  in  the  human  respiratory
tract.
The aim of this investigation was to examine the
effects  of  indomethacin  and  BAY  x1005  (5-lipox-
ygenase inhibitor)  on MUC5AC mucin  release from
human airways in vitro.
Materials and methods
Tissues
Human lung tissues were obtained from patients who
had undergone surgery  for lung  carcinoma. Tissues
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from the tumor area. Subsequently, the bronchi (third
to sixth generation bronchi) were dissected free from
the  parenchyma  tissue  and  washed  with  Tyrode’s
solution, pH 7.4 as previously described by Labat and
coworkers.10 Bronchial  tissues  were  cut  as  rings
(3–6mm  internal  diameter  and  145±33mg  wet
weight). A  total of  55  bronchial  preparations were
examined from lungs of 15 different patients.
Functional protocols
Human bronchial preparations were placed in sepa-
rate wells of a 24-well plate (Costar, UK) containing
1ml of Tyrode’s solution and equilibrated for 1h at
37°C in a humidified incubator (5% CO2/air). At the
end  of  this  equilibration  period,  the  medium  was
exchanged  and  fresh  Tyrode’s  solution  previously
warmed at 37°C was added. After 1h the bronchial
fluids were collected (Period I; basal release). Subse-
quently, fresh Tyrode’s solution or Tyrode’s solution
containing either indomethacin (INDO; 1.7 m M), BAY
x1005 (5-lipoxygenase inhibitor; 1m M) or the combi-
nation (INDO, 1.7 m M/BAY x1005, 1 m M) were added
for 30min  to the  bronchial  preparations. After this
period the  preparations were  then  exposed to  the
drugs  for  1h  (Period  II;  treatment). The  bronchial
fluids  were  collected  at  the  end  of  Period  II.  In
protocols involving ATP the preparations were chal-
lenged with ATP (0.1 mM) during Period II (1h). The
fluids (Periods I and II) were collected and stored at
–20°C until analysis.
Immunoradiometric assay (IRMA)
M1  mucin  isolated from  an  ovarian  mucinous  cyst
fluid was used as standard. Eight MAbs raised against
epitopes  associated  with  the  peptide  core  of  M1
mucin  allowed  the  detection of  mucins.11,12 These
anti-M1 mucin MAbs are IgG1. An immunoradiometric
assay was performed using a mixture of eight anti-M1
mucin  MAbs (PM8), which included both 1–13  M1
and 21 M1 MAbs.
A solid-phase double-antibody-sandwich immunor-
adiometric  assay  (IRMA)  was  used  as  previously
described.13 Polystyrene  stars  (Oris  Industrie,  Saint
Quentin en Yvelines, France) were coated with the
1–13 M1 MAb (10 m g/ml in 0.01M PBS, pH 7.4) by
incubating for 2h at room temperature, rinsed three
times  with  PBS-Tween  20  (0.1%)  and  subsequently
incubated in PBS-BSA (1%)  overnight at 37°C. After
several washings, stars were dried at 40°C and stored
at 4°C until used. The M1 mucin standard (10m g/ml),
as well as human bronchial fluids were serially diluted
in PBS-Tween 20 (0.1%). A volume of 300m l of each
dilution was added to the 1–13 M1 MAb coated-stars
and  incubated  overnight  at  37°C.  Stars  were  then
washed  with  PBS-Tween  20  (0.1%)  and  incubated
with  PM8  MAbs  previously  radiolabelled  with  125I
(5´ 105 cpm/ml) overnight at 37°C. Subsequently, the
stars were washed and the radioactivity was measured
in  a  gamma  counter  (Wizard  Model  147005).  The
concentration  of  mucin  contained  in  the  human
bronchial fluids was estimated from the IRMA stand-
ard  curve  obtained  with  the  M1  mucin  standard.
Mucin concentrations were determined in bronchial
fluids  of  55  preparations  from  15  human  lung
samples.
Calculation
The concentration of MUC5AC mucin detected in the
fluids derived from human bronchial preparations by
the IRMA are expressed as MUC5AC mucin (m g/ml)
and were estimated from the M1 standard curves. All
results  are  means±SEM.  Statistical analysis  was  per-
formed  using  the  Student’s  t-test. A  value  (P<0.05)
was taken as an indication of significance.
Results
The  basal  release  of  MUC5AC  mucin  from  human
bronchial  preparations was not  significantly  altered
during  the  experimental  protocol  under  control
conditions  (Table  1,  Period  I  vs Period  II).  When
bronchial preparations were exposed to either INDO
(1.7 m M) or the 5-LO  inhibitor, (BAY x1005;  1 m M),
the MUC5AC mucin released from bronchial tissues
was not significantly different from those quantities
detected either during control conditions (Period II)
or when compared with data obtained during Period
I (Table 1). Treatment of  human  bronchial prepara-
tions  with the  drug  combination (INDO/5-LO)  also
did not significantly modify the release of MUC5AC
mucin when results were compared with appropriate
control values  (Table 1). In contrast, ATP (0.1 mM)
significantly  increased  the  detection  of  MUC5AC
(approximately  3-fold,  when  compared  either  with
results  obtained  during  Period  I  or  with  control
values, Period II).
Discussion
The cyclooxygenase inhibitor, INDO and/or the 5-LO
inhibitor,  BAY  x1005  did  not  significantly  alter  the
basal release of MUC5AC mucin from human airways
in vitro. The data suggest that metabolites of these
enzymatic pathways may not be involved in the local
regulation  of  human  respiratory  tract  goblet  cell
secretory activity.
Marom  and  coworkers8 have  shown  that  INDO
provoked  a  small  but  significant  increase  in  the
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human bronchial explants. These investigators dem-
onstrated that the release of  radiolabeled glycopro-
tein  increased  approximately  30%  when  tissues
were exposed to INDO. In contrast, the data (pres-
ent  report)  demonstrated  that  release  of  the  spe-
cific  MUC5AC  mucin  found  in  goblet  cells  of  the
surface  epithelium  was  not  modified  by  INDO.
While  an  explanation  for  these  differences  is  not
readily  apparent,  one  possibility  may  be  that  the
labeling  of  the  glycoprotein  pool  with
3H-glucosamine  represents  a  number  of  different
mucins,  some  of  which  may  not  be  altered  by
INDO  treatment. In addition, the  labeled glycopro-
tein  pool  may  also  represent  mucins  derived  from
different secretory elements in the respiratory tract
(goblet  cells  and/or  submucosal  glands).  Further-
more, in the previous reports7,8 the effects of INDO
were  obtained  in  tissues  constantly  exposed  to
hydrocortisone. The  relative  contribution  of  INDO
to  the  increase  glycoprotein  release  may  therefore
be  difficult  to  determine.  In  contrast,  MUC5AC
mucin  is  primarily  associated  with  human  goblet
cells in the epithelium,10 these data suggest that the
goblet  cell  release  of  this  specific  mucin  may  not
be  modified  by  metabolites  of  the  cyclooxygenase
enzymatic pathway.
Marom and coworkers8 also reported that inhibi-
tion of  the 5-lipoxygenase  enzyme either by ETYA,
nordihydroguaiaretic  acid  or  a -naphthol  decreased
mucus  glycoprotein  release.  Since  these  inhibitors
are  known  to  have  anti-oxidant  effects  as  well  as
inhibit other enzymes, interpretation of these results
may  be  compromised  by  the  selectivity  of  these
compounds. However, these observations indirectly
suggested that products of the 15-lipoxygenase meta-
bolic pathway may be responsible for the alterations
in  mucus  glycoprotein.  Hunter  and  coworkers14
showed  that  epithelial  cells  in  culture  released
predominantly products of the 15-lipoxygenase enzy-
matic pathway. Thus the small decrease in release of
mucin8 may  be  due  to  the  mobilization  of  arachi-
donic acid via this latter pathway. While 15-HETE is
known  to  increase  both  secretion  (hillock  forma-
tion)  and  tracheal fluid  in  the  dog,15 there  are  no
reports dealing with inhibition and secretory activity
associated with the 15-lipoxygenase metabolic path-
way in human airways.
In  conclusion,  these  data  suggest  that  although
MUC5AC  from  the  goblet  cells  in  the  surface
epithelium  was  not  modified  by  INDO  and  5-LO
inhibition,  the  release  of  MUC5AC  by  goblet  cells
may  be  affected  by  metabolites  of  the  15-lipox-
ygenase enzymatic pathway. However, further work
will  be  necessary  to  confirm  this  latter  suggestion
when  specific  inhibitors  of  this  pathway  become
available.
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